Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
13.38-0.10 (-0.74%)
At close: 04:00PM EDT
13.30 -0.08 (-0.60%)
After hours: 05:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.48
Open13.47
Bid13.11 x 800
Ask13.79 x 1300
Day's Range13.25 - 13.63
52 Week Range12.39 - 75.68
Volume182,611
Avg. Volume617,556
Market Cap2.503B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac

    Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac N.V. (NASDAQ: CVAC). CureVac, earlier this month, filed a lawsuit in Germany against BioNTech over its use of mRNA technology. Related: CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech. It did not rule out further legal action against BioNTech's p

  • Reuters

    UPDATE 2-BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims

    COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit https://tmsnrt.rs/3PAjBo7, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.

  • Reuters

    BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims

    COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.

Advertisement
Advertisement